TELA Bio (TELA) Liabilities and Shareholders Equity (2018 - 2026)

TELA Bio has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $69.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 9.53% year-over-year to $69.9 million; the trailing twelve-month figure through Mar 2026 stood at $280.4 million (up 1.22% YoY), and the FY2025 full-year result was $81.4 million, down 5.95% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $69.9 million, down from $81.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $94.4 million in Q2 2023, with the low at $51.3 million in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $70.7 million, with a median of $69.9 million recorded in 2026.
• Year-over-year, Liabilities and Shareholders Equity surged 83.87% in 2023 and slumped 39.28% in 2024.
• Tracing TELA's Liabilities and Shareholders Equity over 5 years: stood at $67.9 million in 2022, then rose by 15.02% to $78.0 million in 2023, then advanced by 10.92% to $86.6 million in 2024, then slipped by 5.95% to $81.4 million in 2025, then slipped by 14.16% to $69.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $69.9 million (Q1 2026), $81.4 million (Q4 2025), and $61.6 million (Q3 2025), per Business Quant data.

Peer Comparison